A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 20, 2003, Pages 4389-4415

  Toda, Narihiro ^a   Tago, Keiko ^a   Marumoto, Shinji ^a   Takami, Kazuko ^a   Ori, Mayuko ^a   Yamada, Naho ^a   Koyama, Kazuo ^a   Naruto, Shunji ^a   Abe, Kazumi ^a   Yamazaki, Reina ^a   Hara, Takao ^a   Aoyagi, Atsushi ^a   Abe, Yasuyuki ^a   Kaneko, Tsugio ^a   Kogen, Hiroshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLCARBAMIC ACID 2 METHYL 1 [2 (4 NITROPHENOXY)ETHYL] 2,3 DIHYDRO 1H BENZ[C]AZEPIN 7 YL ESTER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; RECEPTOR BLOCKING AGENT; SEROTONIN TRANSPORTER INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; HUMAN; INHIBITION KINETICS; SIDE EFFECT;

EID: 12444346791     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00452-8     Document Type: Article

References (27)

1. (a) Wurtman R. J. Sci. Am. 252:1985;48.
2. (b) Altman H. J. Alzheimer's Diseases Problems, Prospects and Perspectives. 1987;Plenum, New York.
3. (a) Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowski J. Prog. Brain Res. 98:1993;431.
4. (b) Millard C. B., Broomfield C. A. J. Neurochem. 64:1995;1909.
5. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. N. Engl. J. Med. 315:1983;1241.
6. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. Neurology. 50:1998;136.
7. Forette F., Anand R., Gharabawi G. Eur. J. Neurol. 6:1999;423.
8. (a) Benzi G., Moretti A. Eur. J. Pharmacol. 346:1998;1.
9. Gacobini E. Jpn. J. Pharmacol. 74:1997;225.
10. (a) Berger A. K., Fratiglioni L., Forsell Y., Winblad B., Backman L. Neurology. 53:1999;1998.
11. (b) Harwood D. G., Sultzer D. L., Wheatley M. V. Neuropsychiatry, Neuropsychol. Behav. Neurol. 13:2000;83.
12. Lyketsos C. G., Sheooard J. M., Steele C. D., Kopunek S., Steinberg M., Baker A. S., Brandt J., Rabins P. V. Am. J. Psychiatry. 157:2000;1686.
13. (a) Kogen H., Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T. Org. Lett. 4:2002;3359.
14. (b) Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T., Kogen H. Bioorg. Med. Chem. 11:2003;1935.
15. Golstein J., Schreiber S., Velkeniers B., Vanhaelst L. Eur. J. Pharmacol. 91:1983;239.
16. Nelson N. A., Gelotte K. O., Tamura Y., Sinclair H. B., Schuck J. M., Bauer V. J., White R. W. J. Org. Chem. 26:1961;2599.
17. Sano T., Toda J., Maehara N. Can. J. Chem. 65:1987;94.
18. (a) For a recent review, see: Grubbs R. H., Chang S. Tetrahedron. 54:1998;4413.
19. (b) Fürstner A. Angew. Chem., Int. Ed. 39:2000;3012.
20. (c) Yet L. Chem. Rev. 100:2000;2963.
21. For a recent review, see: Farina V., Krishnamurthy V., Scott W. J. Org. React. 50:1997;1.
22. Kabalka G. W., Shoup T. M., Goudgaon N. M. Tetrahedron Lett. 30:1989;1483.
23. Comins D. L., Dehghani A. Tetrahedron Lett. 33:1992;6299.
24. Mendelson W. L., Holmes M., Dougherty J. Synth. Commun. 26:1996;593.
25. Davies S. G., Walters A. S. J. Chem. Soc., Perkin Trans. 1. 1994;1129.
26. The determination of enantiomeric excess and absolute configuration is described in ref 9(a).
27. Ellman G. L., Courtney D., Andres V. Jr., Featherstone R. M. Biochem. Pharmacol. 7:1961;88.